Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC2 | Q92769 | 3/20 | 0.57 |
| ▸ | DPP4 | P27487 | 2/20 | 0.47 |
| ▸ | MASP2 | O00187 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
| ▸ | F2 | P00734 | 2/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.43 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26574727 | 1.00 | HDAC2 (0.57) | HDAC2DPP4MASP2POLBATM | |
| SCHEMBL7020090 | 1.00 | HDAC2 (0.57) | HDAC2DPP4MASP2POLBATM | |
| Hydrochloric Acid SCHEMBL29035260 | 0.98 | HDAC2 (0.56) | HDAC2DPP4MASP2POLBATM | |
| Hydrochloric Acid SCHEMBL29523781 | 0.98 | HDAC2 (0.56) | HDAC2DPP4MASP2POLBATM | |
| Hydrochloric Acid SCHEMBL29035258 | 0.98 | HDAC2 (0.56) | HDAC2DPP4MASP2POLBATM | |
| SCHEMBL23478581 | 0.88 | HDAC2 (0.43) | HDAC2DPP4MASP2CHEK2RPS6KB1 | |
| SCHEMBL10678627 | 0.85 | SLC6A2 (0.55) | MASP2POLBATMF2 | |
| SCHEMBL29523404 | 0.84 | F2 (0.48) | HDAC2DPP4MASP2F2CHEK2 | |
| SCHEMBL30530712 | 0.84 | F2 (0.48) | HDAC2DPP4MASP2F2CHEK2 | |
| SCHEMBL30530793 | 0.84 | F2 (0.48) | HDAC2DPP4MASP2F2CHEK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9126927-B2 | Amido compounds and their use as pharmaceuticals | INCYTE HOLDINGS CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | INCYTE CORPORATION (US) | 2012-01-19 | — | — | US | disclosed |
| US-8058288-B2 | Amido compounds and their use as pharmaceuticals | INCYTE CORPORATION (US) | 2011-11-15 | — | — | US | disclosed |
| EP-0574174-B1 | Angiotensin II antagonists | LILLY CO ELI (US) | 2003-08-13 | — | — | EP | disclosed |
| US-5693633-A | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1997-12-02 | — | — | US | disclosed |
| US-5612360-A | AROMATIC N-HETEROCYCLIC COMPOUNDS AS HYPOTENSIVE AGENTS WITH ACID GROUPS, SULFONYLCARBOXAMIDES OR TETRAZOLE GROUPS | ELI LILLY AND COMPANY (US) | 1997-03-18 | — | — | US | disclosed |
| US-5569768-A | USEFUL IN TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, GLAUCOMA AND RENAL INSUFFICIENCY | ELI LILLY AND COMPANY (US) | 1996-10-29 | — | — | US | disclosed |
| US-5556981-A | Angiotensin II antagonist intermediates | ELI LILLY AND COMPANY (US) | 1996-09-17 | — | — | US | disclosed |
| CN-1101908-A | Angiotensin II antagonists | LILLY CO ELI (US) | 1995-04-26 | — | — | CN | disclosed |
| EP-0574174-A2 | Angiotensin II antagonists | ELI LILLY AND COMPANY (US) | 1993-12-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120015928-A1 | Amido Compounds And Their Use As Pharmaceuticals | HSD11B1, CYP11B1, HSD11B2 | HDAC2 873/4885DPP4 2276/4885MASP2 3616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.